A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00928486
- Locations
- ๐ฏ๐ต
Nagoya Medical Center, Nagoya-city, Aichi, Japan
๐ฏ๐ตNiigata Cancer Center Hospital, Niigata-city, Niigata, Japan
๐ฏ๐ตKeio University Hospital, Tokyo, Japan
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00915083
- Locations
- ๐บ๐ธ
James Graham Brown Cancer Center, Louisville, Kentucky, United States
๐บ๐ธSarcoma Oncology Center, Santa Monica, California, United States
๐บ๐ธSinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 450
- Registration Number
- NCT00910910
- Locations
- ๐บ๐ธ
Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States
๐ง๐ชHopital de Jolimont, Haine-Saint Paul, Belgium
๐ง๐ชCHU Mont -Godinne, Yvoir, Belgium
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00910858
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 254
- Registration Number
- NCT00875667
- Locations
- ๐ต๐ฑ
Malopolskie Centrum medyczne s.c., Krakรณw, Poland
๐ณ๐ฑIsala Klinieken, Zwolle, Netherlands
๐ง๐ชUZ Brussels, Brussel, Belgium
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 529
- Registration Number
- NCT00864253
- Locations
- ๐บ๐ธ
Loma Linda University Cancer Center, Loma Linda, California, United States
๐บ๐ธMary Crowley Research Center, Dallas, Texas, United States
๐ฆ๐บRoyal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 861
- Registration Number
- NCT00844649
- Locations
- ๐บ๐ธ
Tower Cancer Research Foundation, Beverly Hills, California, United States
๐บ๐ธPhoebe Putney Cancer Center, Albany, Georgia, United States
๐บ๐ธCancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 259
- Registration Number
- NCT00833833
- Locations
- ๐บ๐ธ
Colorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธWinship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2018-04-11
- Lead Sponsor
- Celgene
- Registration Number
- NCT00820768
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 11
- Registration Number
- NCT00812968
- Locations
- ๐ฏ๐ต
Celgene Clinical Site, Shizuoka, Japan